Open access
Sep 2026
Predicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN‐1 Trial
To assess change in long‐term predicted 10‐year cardiometabolic risk (Type 2 diabetes [T2D] and cardiovascular disease [CVD]) in adults with overweight or obesity without T2D.
S. Shinde, Florian Kahles, S. Vasileva-Metodiev et al.
· Diabetes, obesity and metabo... · 0 citations